跳至主要内容
临床试验/EUCTR2010-018862-22-DE
EUCTR2010-018862-22-DE进行中(未招募)不适用

Exploratory study to evaluate different MRI-contrast-agent-application-schemes using Gadovist to optimize contrast enhancement for longer lasting breast examination - Contrast agent application scheme

Kliniken Essen-Mitte0 个研究点目标入组 50 人开始时间: 2010年6月9日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) Adult patients, age 18 years and older
  • 2) with recent diagnosis of breast cancer, histologically proven (within the last 6 weeks before inclusion)
  • 3) referred to contrast-enhanced MRI of the breast for clinical reasons before surgery
  • 4) willing and able to comply with and complete all study procedures
  • 5) who provided written informed consent voluntarily and in person
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1) If female, being pregnant or in nursery (females of childbearing potential must have a negative urine pregnancy test at the day of MRI prior to administration of gadobutrol
  • 2) Any contraindication to the MRI procedure (e.g., metal implants, phobia)
  • 3) Any contraindication to gadolinium-containing MR contrast agents
  • 4) History of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents
  • 5) Having received any contrast agent within 24 hours prior to the MRI examination planned in this study
  • 6) Considered to be clinically unstable or risk of unpredictable clinical course during the study period (e.g., due to previous surgery, acute renal failure)
  • 7) Severe cardiovascular disease (e.g., known long QT syndrome, acute myocardinal infraction [<14 days], unstable angina, congestive heart failure NYHA class IV) or acute stroke (<48 hours)
  • 8) Severly or moderately impaired renal function (GFR calculated with MDRD formular 9) Scheduled or likely to require surgery and/ or biopsy before MRI or within 24 hours after study drug administration
  • 10) Participating in another diagnostic clinical trial
  • 11) Having previously entered this study
  • 12) Patients with a heart rate > 100/ min (measured before the MRI examination)
  • 13) Patients with a blood pressure > Systole/ Diastole 200/ 100 mmHg (measured before the MRI-examination)

研究者

发起方
Kliniken Essen-Mitte

相似试验